Nature Communications | The CHORUS Study of Canakinumab Combined with Chemoradiation and Durvalumab Consolidation in Unresectable Stage III Non-Small Cell Lung Cancer

This study offers a new perspective on immunotherapy strategies for non-small cell lung cancer (NSCLC), suggesting that combining an IL-1β inhibitor with chemoradiation can significantly improve prognosis. It provides critical experimental evidence for the construction of relevant disease models and the design of combination regimens involving immune checkpoint inhibitors.

 

Literature Overview

The article "Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial," published in Nature Communications, systematically explores the efficacy and safety of combining the anti-IL-1β monoclonal antibody Canakinumab with concurrent chemoradiation, followed by consolidation therapy with the PD-L1 inhibitor Durvalumab, in patients with unresectable stage III NSCLC.

Background Knowledge

Although consolidation therapy with Durvalumab following concurrent chemoradiation (cCRT) has become the standard of care for unresectable non-small cell lung cancer, many patients still fail to benefit due to disease progression or toxicity, and recurrence rates remain high. While radiotherapy can induce immunogenic cell death, it simultaneously activates the IL-1β-mediated inflammatory pathway, leading to increased recruitment of myeloid-derived suppressor cells (MDSCs) and dysfunction of CD8+ T cells, thereby limiting therapeutic efficacy. Currently, there is a lack of definitive Phase III clinical evidence for interventions targeting the IL-1β pathway in lung cancer, with most prior studies focusing on advanced-stage patients. This study addresses this gap by utilizing Canakinumab to block radiotherapy-induced IL-1β signaling, aiming to reverse the immunosuppressive microenvironment, enhance sensitivity to chemoradiation, and overcome current bottlenecks in immunotherapy for locally advanced lung cancer.

 

 

Research Methods and Core Experiments

This study is an open-label, non-randomized, single-arm Phase I/II clinical trial (CHORUS) that enrolled 41 patients with unresectable stage III non-small cell lung cancer. The experimental design involved continuous administration of Canakinumab during concurrent chemoradiation and subsequent Durvalumab consolidation therapy. The study assessed the objective response rate (ORR) via imaging, while long-term efficacy was evaluated using progression-free survival (PFS) and overall survival (OS). Additionally, longitudinal peripheral blood immune profiling was conducted using flow cytometry to detect dynamic changes in immune cell subsets such as MDSCs and CTLA-4+ CD8+ T cells, combined with circulating tumor DNA (ctDNA) monitoring to assess tumor burden and molecular response.

Key Conclusions and Perspectives

• Primary Endpoint Achieved: The 24-month PFS rate reached 67%, significantly exceeding the prespecified historical benchmark of 46%, indicating that the IL-1β blockade strategy effectively prolonged patient survival.
• Early Deep Response: At the end of chemoradiation and prior to consolidation therapy, 74% of patients achieved an objective response, and 66% achieved ctDNA clearance at 6 weeks, suggesting that the treatment induced a rapid and profound systemic anti-tumor response.
• Validation of Immune Mechanism: In the responder population, the expansion of MDSCs was significantly inhibited, and the trajectory of exhaustion-associated expansion of CTLA-4+ CD8+ T cells was blocked, confirming that Canakinumab exerts its therapeutic effect by reshaping the immune microenvironment.
• Controllable Safety: The combination regimen did not increase additional severe toxicities. Grade 3-4 adverse events were primarily bone marrow suppression and infections. There were no Canakinumab-related deaths, and the regimen did not lead to discontinuation of Durvalumab.

Research Significance and Prospects

These findings indicate that early intervention in the IL-1β pathway during chemoradiation can effectively reverse radiotherapy-induced immunosuppression, providing a novel combination strategy for drug development in non-small cell lung cancer. These results support the validation of combining IL-1β inhibitors with standard chemoradiation and PD-1/PD-L1 inhibitors in subsequent Phase III clinical trials. Furthermore, dynamic ctDNA monitoring and immune cell subset analysis can serve as key clinical monitoring indicators for evaluating the efficacy of such combination therapies, aiding in the identification of potential beneficiaries and the optimization of treatment timing.

 

 

Conclusion

The CHORUS study, through a deep integration of clinical data and immune mechanisms, confirms that combining an IL-1β blocker significantly improves patient prognosis in the treatment of unresectable stage III non-small cell lung cancer. This study not only addresses the critical disease pain point of radiotherapy-induced immunosuppression but also provides a solid biological basis for optimizing future immunotherapy regimens. From laboratory mechanistic exploration to clinical translation, this strategy is poised to become a cornerstone in reshaping the treatment landscape of locally advanced lung cancer, driving drug development towards more precise and efficient combination therapy models, and ultimately enhancing long-term survival rates and quality of life for patients.

 

Narek Shaverdian, Michael Offin, Nicolas Toumbacaris, Daniel R Gomez, and Jamie E Chaft. Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial. Nature Communications.